Getting an Accurate Diagnosis: Genetics and Lab Reports
At a Glance
Diagnosing NFKB1-related immune dysregulation usually requires more than one test: doctors combine clinical history, antibody levels, vaccine responses, B- and T-cell testing, and genetic findings. A variant of uncertain significance does not confirm the diagnosis and may need functional testing.
An accurate diagnosis of NFKB1-related immune dysregulation is rarely made with a single blood draw. Because this condition is so complex, doctors must piece together a “diagnostic puzzle” that includes your clinical history, detailed immune markers, and advanced genetic testing [1][2].
The Immune Profile: More Than Just Antibodies
While many people first learn they have an immune issue because of low antibody levels (hypogammaglobulinemia), a complete diagnosis requires looking deeper into your “immune compartments” [3]. Note: If you are currently receiving immunoglobulin replacement therapy, your IgG and vaccine response tests may reflect donor antibodies rather than your own.
- Quantitative Immunoglobulins: Doctors check levels of IgG, IgA, and IgM. In NFKB1, about 89% of symptomatic cohort patients have low levels of at least one of these [2].
- Vaccine Responses: A key test for immune function is seeing how your body responds to vaccines (like the pneumonia or tetanus shots). If your body cannot produce “protective titers” (sufficient antibodies) after a vaccine, it suggests a functional defect [4][5].
- B-cell Subsets: This is a specialized test called flow cytometry. In NFKB1, the most common finding (in about 60% of affected patients) is a significant reduction in switched-memory B cells—the “veteran” cells that remember how to fight specific germs [2][6]. You may also see an increase in CD21-low B cells, which are often associated with autoimmunity [6].
- T-cell Analysis: Unlike generic CVID, NFKB1 can also affect T-cells. Your report might show altered overall T-cell counts or an inverted CD4/CD8 ratio, meaning the balance of your immune “commanders” is off [7][8].
Decoding Your Genetic Report
Genetic testing is an essential tool for evaluating NFKB1, but the results can be confusing. Your report will list a variant (a change in the DNA). However, a genetic result must be classified and interpreted with the phenotype; a Variant of Uncertain Significance (VUS) does not confirm the diagnosis.
Most labs classify variants into three main categories:
- Pathogenic / Likely Pathogenic: The change is known to cause disease. Most established NFKB1 disease is caused by heterozygous loss-of-function variants.
- Benign / Likely Benign: The change is a normal human variation and does not cause disease.
- Variant of Uncertain Significance (VUS): This is a “grey area.” It means the lab sees a change, but they don’t have enough data to say if it is harmful or harmless [1][9].
If you have a VUS, your doctor should not assume it is the cause of your symptoms without further proof [2].
Using Functional Testing to Resolve a VUS
If a genetic test is inconclusive, specialists can sometimes utilize “functional assays” in expert or research laboratories to see if the mutation actually breaks the p50 protein [1].
- Protein Expression (Western Blot): This test checks if your cells are actually producing normal amounts of the p105 and p50 proteins. If levels are significantly lower than normal, it supports haploinsufficiency [10][11].
- Luciferase Reporter Assay: This is a “test drive” for your gene. Scientists put the mutated gene into a cell in a lab and measure if it can successfully turn on immune signals [1].
- Localization Studies: Sometimes the protein is made, but it gets stuck in the wrong part of the cell (the cytoplasm) and can’t get into the “control center” (the nucleus) to do its job [12][10].
Your Diagnostic Completeness Checklist
When reviewing your records, ensure you have the following data points. Review them with a genetics professional and your immunologist.
| Report Type | Key Data Points to Look For |
|---|---|
| Immunology Lab | IgG, IgA, IgM, and IgG-subclass levels [3] |
| Vaccine Titers | Pre- and post-vaccination levels for Pneumococcus and Tetanus [4] |
| Flow Cytometry | Absolute B-cell and T-cell counts; Switched-memory B-cell %; CD21-low B-cell % [6] |
| Genetic Report | Exact HGVS notation (e.g., c.123G>A); Variant classification [6] |
| Advanced Genetics | Evidence of Copy Number Variation (CNV) analysis (to look for missing chunks of the gene) [13] |
| Functional Assay | (If VUS) Results of protein stability or NF-κB reporter activity tests [1] |
Confirming an NFKB1 diagnosis is a collaborative effort between you, your immunologist, and often a geneticist. Having these specific reports organized allows your team to move from uncertainty to an individualized care plan [14].
Common questions in this guide
How is NFKB1-related immune dysregulation diagnosed?
What does a VUS in NFKB1 mean?
Can immunoglobulin replacement change my immune test results?
Which immune lab results are important when evaluating NFKB1?
Does NFKB1 testing check for large gene deletions?
What tests can help explain an unclear NFKB1 variant?
What does a pathogenic NFKB1 variant mean?
Get notified when new evidence is published on NFKB1-related immune dysregulation.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (14)
- 1
Biochemically deleterious human NFKB1 variants underlie an autosomal dominant form of common variable immunodeficiency.
Li J, Lei WT, Zhang P, et al.
The Journal of experimental medicine 2021; (218(11)) doi:10.1084/jem.20210566.
PMID: 34473196 - 2
Characterization of the clinical and immunologic phenotype and management of 157 individuals with 56 distinct heterozygous NFKB1 mutations.
Lorenzini T, Fliegauf M, Klammer N, et al.
The Journal of allergy and clinical immunology 2020; (146(4)):901-911 doi:10.1016/j.jaci.2019.11.051.
PMID: 32278790 - 3
Identification of Novel Genetic Variants in CVID Patients With Autoimmunity, Autoinflammation, or Malignancy.
Christiansen M, Offersen R, Jensen JMB, et al.
Frontiers in immunology 2019; (10()):3022 doi:10.3389/fimmu.2019.03022.
PMID: 32047491 - 4
Common Variable Immunodeficiency and Neurodevelopmental Delay Due to a 13Mb Deletion on Chromosome 4 Including the NFKB1 Gene: A Case Report.
Franco-Jarava C, Valenzuela I, Riviere JG, et al.
Frontiers in immunology 2022; (13()):897975 doi:10.3389/fimmu.2022.897975.
PMID: 35784294 - 5
Common variable immunodeficiency due to a novel variant in NFKB1 with a neonatal presentation of parechovirus meningitis and sepsis-like illness.
Szczawińska-Popłonyk A, Popłonyk N, Bernat-Sitarz K, et al.
Allergologia et immunopathologia 2025; (53(3)):31-40 doi:10.15586/aei.v53i3.1307.
PMID: 40342112 - 6
Loss-of-function nuclear factor κB subunit 1 (NFKB1) variants are the most common monogenic cause of common variable immunodeficiency in Europeans.
Tuijnenburg P, Lango Allen H, Burns SO, et al.
The Journal of allergy and clinical immunology 2018; (142(4)):1285-1296 doi:10.1016/j.jaci.2018.01.039.
PMID: 29477724 - 7
Clinical and immunological characterization of NFKB1 haploinsufficiency in Japan.
Moriya K, Kamiyama Y, Ogino R, et al.
Frontiers in immunology 2026; (17()):1866459 doi:10.3389/fimmu.2026.1866459.
PMID: 42488646 - 8
NF-κB1 Haploinsufficiency Causing Immunodeficiency and EBV-Driven Lymphoproliferation.
Boztug H, Hirschmugl T, Holter W, et al.
Journal of clinical immunology 2016; (36(6)):533-40 doi:10.1007/s10875-016-0306-1.
PMID: 27338827 - 9
Detrimental NFKB1 missense variants affecting the Rel-homology domain of p105/p50.
Fliegauf M, Kinnunen M, Posadas-Cantera S, et al.
Frontiers in immunology 2022; (13()):965326 doi:10.3389/fimmu.2022.965326.
PMID: 36105815 - 10
A Pathogenic Missense Variant in NFKB1 Causes Common Variable Immunodeficiency Due to Detrimental Protein Damage.
Fliegauf M, Krüger R, Steiner S, et al.
Frontiers in immunology 2021; (12()):621503 doi:10.3389/fimmu.2021.621503.
PMID: 33995346 - 11
Resolving the polygenic aetiology of a late onset combined immune deficiency caused by NFKB1 haploinsufficiency and modified by PIK3R1 and TNFRSF13B variants.
Hargreaves CE, Dhalla F, Patel AM, et al.
Clinical immunology (Orlando, Fla.) 2022; (234()):108910 doi:10.1016/j.clim.2021.108910.
PMID: 34922003 - 12
Vulnerability to Meningococcal Disease in Immunodeficiency Due to a Novel Pathogenic Missense Variant in NFKB1.
Anim M, Sogkas G, Schmidt G, et al.
Frontiers in immunology 2021; (12()):767188 doi:10.3389/fimmu.2021.767188.
PMID: 35003082 - 13
A large deletion in a non-coding regulatory region leads to NFKB1 haploinsufficiency in two adult siblings.
Fusaro M, Coustal C, Barnabei L, et al.
Clinical immunology (Orlando, Fla.) 2024; (261()):110165 doi:10.1016/j.clim.2024.110165.
PMID: 38423196 - 14
Common Variable Immunodeficiency Disorders: A perspective from New Zealand.
Ameratunga R, J Longhurst H, Lehnert K, et al.
Clinical reviews in allergy & immunology 2025; (68(1)):105 doi:10.1007/s12016-025-09099-2.
PMID: 41324804
This page explains NFKB1-related immune dysregulation testing for educational purposes and does not replace medical advice. Your immunologist and genetics professional should interpret your results and decide whether further testing is needed.